Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: A multicenter randomized controlled study

Open Forum Infectious Diseases

Volumn 4, Issue 3, 2017, Pages

  Nakamura, Shigeki ^a,e   Miyazaki, Taiga ^a,b   Izumikawa, Koichi ^b   Kakeya, Hiroshi ^c   Saisho, Yutaka ^d   Yanagihara, Katsunori ^b   Miyazaki, Yoshitsugu ^e   Mukae, Hiroshi ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

High risk patient; Influenza; Neuraminidase inhibitor; Oseltamivir; Peramivir

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; PARACETAMOL; PERAMIVIR;

AGED; ARTICLE; ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; IC50; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SYMPTOM; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TYPING;

EID: 85053387258     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofx129     Document Type: Article

References (27)

1. Muthuri SG, MyIes PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health Importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207:553–63.
2. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2013;7:76–81.
3. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395–404.
4. World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses. Geneva, Switzerland: World Health Organization; 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf
5. Hikita T, Hikita H, Hikita F, et al. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr. 2012;2012:834181.
6. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(HINl) pdm09 infection: an observational study in the 2010–2011 influenza season in Japan. J Infect Chemother. 2012;18:858–64.
7. Takemoto Y, Asai T, Ikezoe I, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012–2013. Chemotherapy. 2013;59:373–8.
8. Sugaya N, Sakai-Tagawa Y, Bamba M, et al. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Antivir Ther. 2015;20:49–55.
9. Kohno S, Kida H, Mizuguchi M, et al; S-021812 Clinical Study Group. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55:2803–12.
10. Nasu T, Ogawa D, Wada J, Makino H. Peramivir for severe influenza infection in a patient with diabetic nephropathy. Am J Respir Crit Care Med. 2010;182:1209–10.
11. Hung S-F, Fung C-P, Perng D-W, Wang F-D. Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus. J Microbiol Immunol Infect. 2015. http://dx.doi.org/10.1016/j.jmii.2015.08.016
12. Boltz DA, Ilyushina NA, Arnold CS, et al. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008;80:150–7.
13. Tanaka A, Nakamura S, Seki M, et al. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice. Antivir Ther. 2015;20:11–9.
14. Kitano M, Kodama M, Itoh Y, et al. Efficacy of repeated intravenous infection of peramivir against influenza A (H1N1) 2009 virus injection in immunosuppressed mice. Antimicrob Agents Chemother. 2013;57:2286–94.
15. Saisho Y, Ishibashi T, Fukuyama H, et al. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. Antivir Ther. 2016; doi:10.3851/IMP3104.
16. Kohno S, Yen MY, Cheong HJ, et al; S-021812 Clinical Study Group. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55:5267–76.
17. Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Investig. 2003;23:561–9.
18. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother. 2010;65:ii11–ii24.
19. Patrick M, Sebstian LJ. Influenza infection and COPD. Int J Chron Obstruct Pulmon Dis. 2007;2:55–64.
20. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568–75.
21. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65:510–5.
22. Coffin SE, Leckerman K, Keren R, et al. Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J. 2011;30:962–6.
23. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492–500.
24. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014;59:e172–85.
25. Louie JK, Yang S, Yen C, et al. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS One. 2012;7:e40261.
26. Division of Acquired Immunodeficiency Syndrome, NIAID, NIH. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf. Accessed December 2004.
27. Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568–74.